NCT01794507 - A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 19, 2012

Primary Completion Date

July 16, 2019

Study Completion Date

July 16, 2019

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG

ABT-199

ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort

DRUG

bortezomib

Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort

DRUG

dexamethasone

Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.

Trial Locations (9)

Peter MacCallum Cancer Ctr /ID# 79553, Melbourne

Royal Melbourne Hospital /ID# 79533, Parkville

Mayo Clinic /ID# 121495, Jacksonville

CHU de Nantes, Hotel Dieu -HME /ID# 78773, Nantes

University of Michigan Hospitals /ID# 80353, Ann Arbor

CHRU Lille - Hôpital Claude Huriez /ID# 77234, Lille

University of Arizona Cancer Center - North Campus /ID# 117876, Tucson

Northwestern University Feinberg School of Medicine /ID# 117477, Chicago

Mayo Clinic - Rochester /ID# 77235, Rochester